Federation des caisses Desjardins du Quebec Buys 1,500 Shares of argenex SE $ARGX

Federation des caisses Desjardins du Quebec lifted its position in shares of argenex SE (NASDAQ:ARGX - Free Report) by 105.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,921 shares of the company's stock after acquiring an additional 1,500 shares during the quarter. Federation des caisses Desjardins du Quebec's holdings in argenex were worth $1,729,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. RTW Investments LP raised its position in shares of argenex by 2.9% during the fourth quarter. RTW Investments LP now owns 673,497 shares of the company's stock worth $414,201,000 after acquiring an additional 19,067 shares during the last quarter. Lord Abbett & CO. LLC grew its stake in shares of argenex by 33.2% during the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company's stock worth $162,585,000 after purchasing an additional 68,498 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of argenex by 22.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 176,450 shares of the company's stock worth $100,063,000 after purchasing an additional 32,239 shares during the period. Braidwell LP grew its stake in shares of argenex by 99.2% during the first quarter. Braidwell LP now owns 160,849 shares of the company's stock worth $95,201,000 after purchasing an additional 80,083 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in shares of argenex during the fourth quarter worth $91,013,000. Institutional investors own 60.32% of the company's stock.

argenex Trading Down 1.1%

Shares of ARGX stock traded down $8.28 on Friday, hitting $755.25. 59,043 shares of the stock were exchanged, compared to its average volume of 374,859. The firm has a market capitalization of $46.22 billion, a P/E ratio of 38.73, a price-to-earnings-growth ratio of 0.81 and a beta of 0.41. The business has a 50-day moving average of $645.47 and a 200 day moving average of $606.10. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $779.03.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.90. The company had revenue of $866.79 million during the quarter, compared to analysts' expectations of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. As a group, research analysts forecast that argenex SE will post 3.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on ARGX. Wedbush reaffirmed an "outperform" rating and set a $800.00 price objective on shares of argenex in a research note on Monday, August 25th. Wall Street Zen raised argenex from a "hold" rating to a "buy" rating in a research note on Saturday, September 6th. Morgan Stanley lifted their price objective on argenex from $700.00 to $766.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. JPMorgan Chase & Co. lifted their price objective on argenex from $775.00 to $830.00 and gave the stock an "overweight" rating in a research note on Monday, August 4th. Finally, Citigroup reaffirmed a "buy" rating on shares of argenex in a research note on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $772.84.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.